

Laura Mezquita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7629805/publications.pdf>

Version: 2024-02-01

112
papers

9,240
citations

159585

30
h-index

43889

91
g-index

114
all docs

114
docs citations

114
times ranked

12995
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. <i>Lung Cancer</i> , 2022, 166, 255-264.	2.0	13
2	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2022, 103, 102335.	7.7	19
3	CD8 ⁺ PD-1 ⁺ to CD4 ⁺ PD-1 ⁺ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. , 2022, 10, e004012.		16
4	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
5	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.	2.8	32
6	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	0
7	Vaccine Therapy in Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2022, 10, 740.	4.4	4
8	Documento de consenso de la Sociedad Española de Cirugía Torácica (SECT). Seguimiento a largo plazo de los pacientes operados de cáncer de pulmón. <i>Cirugía Española (English Edition)</i> , 2022, , .	0.1	1
9	Radon and Lung Cancer: Current Trends and Future Perspectives. <i>Cancers</i> , 2022, 14, 3142.	3.7	37
10	The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2551-2551.	1.6	0
11	Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e54-e56.	2.6	3
12	The Role of Violent Video Game Exposure, Personality, and Deviant Peers in Aggressive Behaviors Among Adolescents: A Two-Wave Longitudinal Study. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2021, 24, 32-40.	3.9	10
13	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
14	Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.3	8
15	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	2.8	42
16	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The plue study. <i>Lung Cancer</i> , 2021, 155, 114-119.	2.0	12
17	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	2.8	24
18	Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer. <i>Cancer Research</i> , 2021, 81, 448-448.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Npj Precision Oncology</i> , 2021, 5, 67.	5.4	17
20	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	3.7	5
21	Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, 13, 1176. <i>Cancers</i> , 2021, 13, 3624.	3.7	2
22	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. <i>Lung Cancer</i> , 2021, 159, 45-55.	2.0	23
23	Integrin- α V-mediated activation of TGF- β 2 regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. <i>Nature Communications</i> , 2021, 12, 5209.	12.8	30
24	A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1782-1784.	1.1	1
25	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.	5.4	11
26	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	7.0	114
27	Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient. <i>Annals of Thoracic Surgery</i> , 2020, 109, e397-e399.	1.3	3
28	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 383-391.	1.1	58
29	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 122, 340-347.	6.4	24
30	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1147-1157.	6.4	103
31	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020, 12, 2827.	3.7	35
32	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	3.0	25
33	CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. <i>Cell Reports Medicine</i> , 2020, 1, 100127.	6.5	70
34	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020, 12, 3625.	3.7	27
35	Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations. <i>Future Oncology</i> , 2020, 16, 1665-1668.	2.4	1
36	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. <i>Cancers</i> , 2020, 12, 2234.	3.7	31

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. <i>Respiratory Medicine and Research</i> , 2020, 78, 100788.	0.6	2
38	The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 967-970.	2.8	13
39	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	5.4	16
40	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	7.0	23
41	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3758.	3.7	4
42	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	2.6	1
43	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	2.8	53
44	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. <i>PLoS ONE</i> , 2020, 15, e0234302.	2.5	13
45	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	7.1	70
46	Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. <i>European Journal of Cancer</i> , 2020, 129, 71-79.	2.8	45
47	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100023.	1.1	11
48	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	1.1	119
49	Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e497-e510.	2.6	35
50	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	1.1	29
51	Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102906.	4.4	43
52	Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. <i>European Radiology</i> , 2020, 30, 5021-5028.	4.5	10
53	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	3.0	36
54	Abstract 1867: Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
55	Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.. Journal of Clinical Oncology, 2020, 38, 545-545.	1.6	3
56	Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.. Journal of Clinical Oncology, 2020, 38, 735-735.	1.6	5
57	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 162-174.	0.7	38
58	Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence.. Journal of Clinical Oncology, 2020, 38, 9535-9535.	1.6	0
59	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future Oncology, 2020, 16, 1659-1664.	2.4	2
60	Pseudoprogressi3n en una paciente con adenocarcinoma pulmonar metast3sico tratada con nivolumab. Archivos De Bronconeumologia, 2019, 55, 168-169.	0.8	0
61	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 1149-1160.	2.0	9
62	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. Journal of Thoracic Oncology, 2019, 14, 1400-1407.	1.1	23
63	Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC. Journal of Thoracic Oncology, 2019, 14, e215-e216.	1.1	6
64	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Frontiers in Immunology, 2019, 10, 1505.	4.8	34
65	Letter to the Editor about Sorich etAl.. Journal of Thoracic Oncology, 2019, 14, e209.	1.1	5
66	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661988553.	2.6	32
67	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Nonâ€“Small-Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6671-6682.	7.0	95
68	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology, 2019, 30, 1321-1328.	1.2	842
69	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 116, 182-189.	2.8	36
70	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Nonâ€“Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2019, 20, 305-312.e3.	2.6	7
71	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2019, 42, 1230-1239.	2.0	2
72	Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	31

#	ARTICLE	IF	CITATIONS
73	Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts). <i>Annals of Oncology</i> , 2019, 30, ii48.	1.2	0
74	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1244-1254.	1.1	178
75	Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 108, 88-96.	2.8	36
76	Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 102-102.	1.6	72
77	Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (iO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9107-9107.	1.6	10
78	Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2015-2015.	1.6	0
79	Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3055-3055.	1.6	0
80	Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer. , 2019, , .		0
81	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 301-322.	1.1	43
82	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	7.1	599
83	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
84	Durvalumab in non-small-cell lung cancer patients: current developments. <i>Future Oncology</i> , 2018, 14, 205-222.	2.4	12
85	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018, 88, 38-47.	2.8	248
86	<i>EGFR</i> C797S, <i>EGFR</i> T790M and <i>EGFR</i> sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. <i>Oncotarget</i> , 2018, 9, 37393-37406.	1.8	34
87	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	1.6	747
88	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.	1.4	57
89	Safety of osimertinib in <i>EGFR</i>-mutated non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1239-1248.	2.4	25
90	Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer. <i>PLoS ONE</i> , 2018, 13, e0204490.	2.5	24

#	ARTICLE	IF	CITATIONS
91	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	7.1	567
92	Durvalumab for the treatment of non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 627-639.	2.5	38
93	The role of brigatinib in crizotinib-resistant non-small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 123-130.	1.9	14
94	Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, e215-e217.	1.1	12
95	Nivolumab-induced pneumonitis complicated by cyst formation. <i>Lung Cancer</i> , 2018, 122, 258-259.	2.0	2
96	Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12038-12038.	1.6	3
97	Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3015.	1.6	4
98	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9003-9003.	1.6	16
99	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9010-9010.	1.6	40
100	An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9095-9095.	1.6	1
101	Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15102-e15102.	1.6	3
102	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017, 60, 60-68.	7.7	125
103	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2017, 112, 10-15.	2.0	3
104	Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.. <i>Journal of Thoracic Disease</i> , 2016, 8, 2997-3002.	1.4	5
105	Spontaneous tumor lysis syndrome in the setting of small cell lung cancer: Report of two cases and review of the literature. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 92-95.	1.7	7
106	Sumario ejecutivo de las recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. <i>Archivos De Bronconeumología</i> , 2016, 52, 378-388.	0.8	20
107	Síndrome neurológico progresivo inusual en adenocarcinoma de pulmón epidermal growth factor receptor mutado: carcinomatosis menácea invasiva, un diagnóstico de autopsia. <i>Archivos De Bronconeumología</i> , 2016, 52, 571-572.	0.8	0
108	Congenital Bronchial Artery to Pulmonary Artery Fistula in a Patient With Lung Cancer Involving the Carina. <i>Annals of Thoracic Surgery</i> , 2016, 101, e89.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Acrometástasis como presentación inicial de un adenocarcinoma de pulmón en una mujer joven. Archivos De Bronconeumologia, 2016, 52, 482-483.	0.8	4
110	Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9034-9034.	1.6	11
111	Central nervous system progression and liquid biopsy in patients with oncogene addicted non-small cell lung cancer treated with ALK/ROS1 inhibitors. Precision Cancer Medicine, 0, 3, 25-25.	1.8	0
112	Targeting molecular alterations in non-small-cell lung cancer: what's next?. Personalized Medicine, 0, , .	1.5	4